Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 1

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---

    Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at March 31, 2025 and December 31, 2024 
     -  
     – 

    Common stock - $0.01 par value (112,500,000 shares authorized; 14,620,754 and 14,500,707 shares issued at March 31, 2025 and December 31, 2024, respectively; and 14,620,732 and 14,500,685 shares outstanding at March 31, 2025 and December 31, 2024, respectively) 
     146,207  
     145,007 
  
    Additional paid-in capital 
     411,296,548  
     410,987,523 
  
    Accumulated deficit 
     (410,905,539) 
     (406,803,044)
  
    Total stockholders’ equity before treasury stock 
     537,216  
     4,329,486 

    Treasury stock, at cost (22 shares at March 31, 2025 and December 31, 2024) 
     (85,188) 
     (85,188)
  
    Total stockholders’ equity 
     452,028  
     4,244,298 

    Total liabilities and stockholders’ equity 
    $6,862,086  
    $9,717,364 

See accompanying notes to the unaudited condensed
consolidated financial statements.

2

IMUNON, INC.

CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS

(Unaudited)

    For the Three Months Ended March 31, 

    2025  
    2024 

    Operating expenses: 

    Research and development 
    $2,165,092  
    $3,293,861 
  
    General and administrative 
     1,980,207  
     1,717,585 
  
    Total operating expenses 
     4,145,299  
     5,011,446 

    Loss from operations 
     (4,145,299) 
     (5,011,446)

    Other income (expense): 

    Investment income, net 
     42,804  
     81,921